The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Refining multimodal lung cancer therapies
Whilst the advent of systemic therapies and immunotherapies have resulted in improved outcomes for patients with lung cancer, local control of the tumor remains an important focus. Charles Simone, MD, FACRO, New York Proton Center & Memorial Sloan Kettering Cancer Center, New York, NY, discusses strategies to improve multimodal treatment for patients with lung cancer to further optimize patient survival. Radiotherapy remains especially important for oligometastatic and oligoprogressive non-small cell lung cancer (NSCLC) and by improving dosage and radioprotective agents, patients can benefit more from multimodal therapies. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
